Péptidos, lagartos y diseño de fármacos…
611
20.
Kirkpatrick, A.; Heo, J.; Abrol, R.; Goddard III, W. A. (2012). Predicted structure of agonist-‐
bound glucagon-‐like peptide 1 receptor, a class B G protein-‐coupled receptor.
P. Natl. Acad.
Sci. USA
109, 19988–19993.
21.
Runge, S.; Thøgersen, H.; Madsen, K.; Lau, J.; Rudolph, R. (2008) Crystal structure of the
ligand-‐bound Glucagon-‐Like Peptide-‐1 receptor extracellular domain
. J. Biol. Chem
. 283,
11340-‐11347.
22.
Rosenstock, J.; Balas, B.; Charbonnel, B.; Bolli, G. B.; Boldrin, M.; Ratner, R.; Balena, R.
(2013) The fate of taspoglutide, a weekly GLP-‐1 receptor agonist, versus twice-‐daily
exenatide for type 2 diabetes: The T-‐emerge 2 trial.
Diabet. Care
36, 498-‐504.
23.
Garber, A. J. (2011). Long-‐acting Glucagon-‐Like Peptide 1 receptor agonists.
Diabet. Care
34(S2), S-‐279-‐S284.
24.
Kratz, F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
(2008).
J. Control. Release
132, 171-‐183.
25.
Nauck, M.; Petrie, J. R.; Sesti, G.; Mannucci, E.; Courreges, J.-‐P.; Atkin, R.; Düring, S.; Jensen,
M.; Heller, C. B. (2012). The once-‐weekly human GLP-‐1 analogue semaglutide provides
ght in patients with type 2 diabetes.
26.
(consultado el 07-‐08-‐2013).
27.
. J. (2012). Fc-‐fusion proteins: new
Med.
4, 1015–1028.
28.
Glaesner, W.; Vick, A. M.; Millican, R.; Ellis, B.; Tschang, S. H.; Tian, Y.; Bokvist, K.; Brenner,
M.; Koester, A.; Porksen, N.; Etgen, G.; Bumol, T. (2011). Engineering and characterization
of the long-‐acting Glucagon-‐Like Peptide-‐1 analogue LY2189265, an Fc fusion protein.
Diabet Metab. Res. R v.
26, 287–296.
29.
Schellenberger, V.; Wang, C. W.; Geething, N. C.; Spink, B. J.; Campbell, A.; To, W.; Scholle, M.
D.; Yin, Y.; Yao, Y.; Bogin, O.; Cleland, J. L.; Silverman, J.; Stemmer, W. P. C. (2009). A
le
30.
‐
(consultado el 12-‐08-‐2013).
31.
Russell-‐Jones, D.; Gough, S. (2012). Recent advances in incretin-‐based therapies.
Clin.
Endocrinol.
77, 489–499.
32.
Sivertsen, J.; Rosenmeier, J.; Holst, J. J.; Vilsbøll, V. (2012). The effect of Glucagon-‐Like
Peptide 1 on cardiovascular risk.
Nat. Rev. Cardiol
. 9, 209-‐222.
33.
Cai, Y.; Wei, L.; Ma, L.; Huang, X.; Tao, A.; Liu, Z.; Yuan, W. (2013). Long-‐acting preparations
of exenatide.
Drug Des. Devel. Ther.
2013:7 963–970.
34.
Ballav, C.; Gough, S (2012). Bydureon: long-‐acting exenatide for once-‐weekly injection.
Prescriber
23, 30-‐33.
35.
Krause, A. (2011). Exenatide LAR: A sustained-‐release formulation of exenatide for the
treatment of type 2 diabetes.
Formulary
45, 43-‐51.
36.
DeYoung, M. B.; MacConell, L.; Sarin, V.; Trautmann, M.; Herbert, P. (2012). Encapsulation
of exenatide in poly-‐(
D
,
L
-‐lactide-‐co-‐glycolide) microspheres produced an investigational
2 diabetes.
Diabet. Technol. Ther
. 13, 1145-‐
37.
(consultado el 20-‐08-‐2013).
38.
Carr, J. P.; Lautenbach, S. D. (2008). DUROS
®
t consistent rate continuously for 3 to 12
months.
J. Diabetes Sci. Technol
. 2, 461-‐467.
39.
Henry, R. D.; Rosenstock, J.; Logan, D. K.; Alessi, T. R.; Luskey, K.; Baron, M. A. (2013).
Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus
type 2.
Diabetes Care
36, doi:
40.
(consultado el 02-‐08-‐2013).
41.
ig, M. (2003). Structural basis of
human Dipeptidyl Peptidase-‐IV.
Structure
11, 947–959.
